Skip to main content

Table 3 Meta-analysis results using reported multivariable adjusted data

From: Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis

Analysis for adjusted mortality data

Studies (N)

Adjusted HR (95% CI)

Totally high-risk patient populations

5

4.67 (2.18, 9.99); I2 = 77.7%

 Low risk of bias

4

4.62 (1.87, 11.42); I2 = 83.3%

 CS infection comparator

2

2.07 (1.22, 3.53); I2 = 0.0%

 No CR infection comparator

2

8.63 (4.12, 18.08); I2 = 31.6%

 No infection comparator

1

6.92 (3.24, 14.79)

 Longer-term (> 30 days) mortality

4

6.67 (3.88, 11.49); I2 = 0.0%

 Italy

2

4.53 (0.78, 26.20); I2 = 93.3%

 USA

3

5.19 (2.99, 9.01); I2 = 0.0%

Partially and totally high-risk patient populations

8

3.38 (1.93, 5.94); I2 = 76.0%

 Low risk of bias

6

3.87 (2.10, 7.13); I2 = 76.9%

 CS infection comparator

4

1.93 (1.24, 2.99); I2 = 8.2%

 No CR infection comparator

2

8.63 (4.12, 18.08); I2 = 31.6%

 No infection comparator

2

4.08 (1.56, 10.65); I2 = 76.5%

 In-hospital/≤30-day mortality

4

2.05 (1.39, 3.02); I2 = 16.9%

 Longer-term (> 30 days) mortality

4

6.67 (3.88, 11.49); I2 = 36.6%

 CRKP studies only

7

3.45 (1.83, 6.51); I2 = 79.3%

 Studies reporting HR

6

4.17 (2.23, 7.80); I2 = 76.6%

 Studies reporting OR

2

1.71 (0.60, 4.82); I2 = 60.1%

 Italy

2

4.53 (0.78, 26.20); I2 = 93.3%

 USA

6

3.02 (1.79, 5.08); I2 = 54.2%

  1. CI Confidence interval, CRKP Carbapenem-resistant Klebsiella pneumoniae, CS Carbapenem-susceptible, HR Hazard ratio, N Number, OR Odds ratio